281 related articles for article (PubMed ID: 34085047)
1. A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance.
Arriaga JM; Panja S; Alshalalfa M; Zhao J; Zou M; Giacobbe A; Madubata CJ; Kim JY; Rodriguez A; Coleman I; Virk RK; Hibshoosh H; Ertunc O; Ozbek B; Fountain J; Jeffrey Karnes R; Luo J; Antonarakis ES; Nelson PS; Feng FY; Rubin MA; De Marzo AM; Rabadan R; Sims PA; Mitrofanova A; Abate-Shen C
Nat Cancer; 2020 Nov; 1(11):1082-1096. PubMed ID: 34085047
[TBL] [Abstract][Full Text] [Related]
2. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
3. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
[TBL] [Abstract][Full Text] [Related]
4. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
5. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.
Cho H; Herzka T; Zheng W; Qi J; Wilkinson JE; Bradner JE; Robinson BD; Castillo-Martin M; Cordon-Cardo C; Trotman LC
Cancer Discov; 2014 Mar; 4(3):318-33. PubMed ID: 24444712
[TBL] [Abstract][Full Text] [Related]
6. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
[TBL] [Abstract][Full Text] [Related]
7. MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway.
Yang Q; Lang C; Wu Z; Dai Y; He S; Guo W; Huang S; Du H; Ren D; Peng X
J Exp Clin Cancer Res; 2019 Sep; 38(1):391. PubMed ID: 31488180
[TBL] [Abstract][Full Text] [Related]
8. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiling identifies a unique androgen-mediated inflammatory/immune signature and a PTEN (phosphatase and tensin homolog deleted on chromosome 10)-mediated apoptotic response specific to the rat ventral prostate.
Desai KV; Michalowska AM; Kondaiah P; Ward JM; Shih JH; Green JE
Mol Endocrinol; 2004 Dec; 18(12):2895-907. PubMed ID: 15358834
[TBL] [Abstract][Full Text] [Related]
10. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
11. Combined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate Cancer.
Hubbard GK; Mutton LN; Khalili M; McMullin RP; Hicks JL; Bianchi-Frias D; Horn LA; Kulac I; Moubarek MS; Nelson PS; Yegnasubramanian S; De Marzo AM; Bieberich CJ
Cancer Res; 2016 Jan; 76(2):283-92. PubMed ID: 26554830
[TBL] [Abstract][Full Text] [Related]
12. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression.
Ding Z; Wu CJ; Chu GC; Xiao Y; Ho D; Zhang J; Perry SR; Labrot ES; Wu X; Lis R; Hoshida Y; Hiller D; Hu B; Jiang S; Zheng H; Stegh AH; Scott KL; Signoretti S; Bardeesy N; Wang YA; Hill DE; Golub TR; Stampfer MJ; Wong WH; Loda M; Mucci L; Chin L; DePinho RA
Nature; 2011 Feb; 470(7333):269-73. PubMed ID: 21289624
[TBL] [Abstract][Full Text] [Related]
13. Single-cell sequencing reveals MYC targeting gene MAD2L1 is associated with prostate cancer bone metastasis tumor dormancy.
Wang X; Yu J; Yan J; Peng K; Zhou H
BMC Urol; 2022 Mar; 22(1):37. PubMed ID: 35305591
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Targeting of CD146/MCAM Reduces Bone Metastasis in Prostate Cancer.
Zoni E; Astrologo L; Ng CKY; Piscuoglio S; Melsen J; Grosjean J; Klima I; Chen L; Snaar-Jagalska EB; Flanagan K; van der Pluijm G; Kloen P; Cecchini MG; Kruithof-de Julio M; Thalmann GN
Mol Cancer Res; 2019 May; 17(5):1049-1062. PubMed ID: 30745464
[TBL] [Abstract][Full Text] [Related]
15. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer.
Chen WY; Liu SY; Chang YS; Yin JJ; Yeh HL; Mouhieddine TH; Hadadeh O; Abou-Kheir W; Liu YN
Oncotarget; 2015 Jan; 6(1):441-57. PubMed ID: 25436980
[TBL] [Abstract][Full Text] [Related]
17. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
[TBL] [Abstract][Full Text] [Related]
18. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
[TBL] [Abstract][Full Text] [Related]
19. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
[TBL] [Abstract][Full Text] [Related]
20. Alterations in mRNA levels for growth-related genes after transplantation into castrated hosts in oncogene-induced clonal mouse prostate carcinoma.
Egawa S; Kadmon D; Miller GJ; Scardino PT; Thompson TC
Mol Carcinog; 1992; 5(1):52-61. PubMed ID: 1543541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
